H3B-6527
Pwodwi detay
Tags pwodwi
| Gwosè pake | Disponibilite | Pri (USD) |
| 100 mg | Nan stock | 500 |
| 500 mg | Nan stock | 775 |
| 1g | Nan stock | 1750 |
| Plis gwosè | Jwenn Quotes | Jwenn Quotes |
Non Chimik:
N-(2-((6-(3-(2,6-dikloro-3,5-dimethoxyphenyl)-1-methylureido)pirimidin-4-yl)amino)-5-(4-ethylpiperazin-1-yl) fenil) akrilamid
Kòd SMILES:
C=CC(NC1=CC(N2CCN(CC)CC2)=CC=C1NC3=NC=NC(N(C(NC4=C(Cl)C(OC))=CC(OC)=C4Cl)=O)C) =C3)=O
Kòd InChi:
InChI=1S/C29H34Cl2N8O4/c1-6-25(40)35-20-14-18(39-12-10-38(7-2)11-13-39)8-9-19(20)34- 23-16-24(33-17-32-23)37(3 )29(41)36-28-26(30)21(42-4)15-22(43-5)27(28)31/h6,8-9,14-17H,1,7,10-13H2 ,2-5H3,(H,35,40)(H,36,41)(H,32,33,34)
InChi kle:
MBWRLLRCTIYXDW-UHFFFAOYSA-N
Mot:
H3B-6527, H3B 6527, H3B6527, 1702259-66-2
Solibilite:Soluble nan DMSO
Depo:0 - 4 ° C pou kout tèm (jou a semèn), oswa -20 ° C pou tèm long (mwa).
Deskripsyon:
H3B-6527 (H3 Biomedicine) se yon inibitè FGFR4 trè selektif ak aktivite antitumoral ki pisan nan liy selil ak sourit anplifye FGF19.
Sib: FGFR4
